AR003959A1 - Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable. - Google Patents
Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable.Info
- Publication number
- AR003959A1 AR003959A1 ARP960103028A AR10302896A AR003959A1 AR 003959 A1 AR003959 A1 AR 003959A1 AR P960103028 A ARP960103028 A AR P960103028A AR 10302896 A AR10302896 A AR 10302896A AR 003959 A1 AR003959 A1 AR 003959A1
- Authority
- AR
- Argentina
- Prior art keywords
- prepare
- stable hydrazone
- elements
- biologically active
- reagent
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title abstract 4
- 150000007857 hydrazones Chemical group 0.000 title abstract 3
- 239000012217 radiopharmaceutical Substances 0.000 title abstract 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/476,296 US5750088A (en) | 1993-03-30 | 1995-06-07 | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003959A1 true AR003959A1 (es) | 1998-09-30 |
Family
ID=23891282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960103028A AR003959A1 (es) | 1995-06-07 | 1996-06-07 | Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable. |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US5750088A (enExample) |
| EP (1) | EP0832068B1 (enExample) |
| JP (1) | JPH11507364A (enExample) |
| KR (1) | KR19990022573A (enExample) |
| CN (1) | CN1192733A (enExample) |
| AR (1) | AR003959A1 (enExample) |
| AT (1) | ATE233241T1 (enExample) |
| AU (1) | AU718683B2 (enExample) |
| BR (1) | BR9609003A (enExample) |
| CA (1) | CA2222183A1 (enExample) |
| CZ (1) | CZ380197A3 (enExample) |
| DE (1) | DE69626392T2 (enExample) |
| EA (1) | EA000742B1 (enExample) |
| EE (1) | EE9700313A (enExample) |
| ES (1) | ES2193245T3 (enExample) |
| HR (1) | HRP960250A2 (enExample) |
| HU (1) | HUP9901469A3 (enExample) |
| IL (1) | IL118468A0 (enExample) |
| LT (1) | LT4380B (enExample) |
| LV (1) | LV12044B (enExample) |
| MX (1) | MX9709126A (enExample) |
| MY (1) | MY133974A (enExample) |
| NO (1) | NO975678L (enExample) |
| NZ (1) | NZ310799A (enExample) |
| PL (1) | PL323995A1 (enExample) |
| SI (1) | SI9620076B (enExample) |
| SK (1) | SK163497A3 (enExample) |
| WO (1) | WO1996040637A1 (enExample) |
| ZA (1) | ZA964854B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2249025A1 (en) * | 1996-03-13 | 1997-09-18 | Du Pont Pharmaceuticals Company | New ternary radiopharmaceutical complexes |
| ATE240123T1 (de) * | 1996-10-07 | 2003-05-15 | Bristol Myers Squibb Pharma Co | Radiopharmazeutische mittel zur bildgebung von infektionen und entzündungen |
| US6416733B1 (en) | 1996-10-07 | 2002-07-09 | Bristol-Myers Squibb Pharma Company | Radiopharmaceuticals for imaging infection and inflammation |
| US20030124053A1 (en) * | 1996-10-07 | 2003-07-03 | Barrett John Andrew | Radiopharmaceuticals for imaging infection and inflammation |
| US6403054B1 (en) | 1997-05-28 | 2002-06-11 | Bristol-Myers Squibb Pharma Company | Ternary ligand complexes useful as radiopharmaceuticals |
| US6524553B2 (en) | 1998-03-31 | 2003-02-25 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6537520B1 (en) * | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| WO1999051628A1 (en) * | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer |
| HRP990317A2 (en) * | 1998-10-13 | 2000-06-30 | Du Pont Pharm Co | A process for the preparation of a thrombus imaging agent |
| US6794518B1 (en) * | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| CA2349333A1 (en) * | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
| CA2727746A1 (en) | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | Quinolone vitronectin receptor antagonist pharmaceuticals |
| US6511649B1 (en) | 1998-12-18 | 2003-01-28 | Thomas D. Harris | Vitronectin receptor antagonist pharmaceuticals |
| BR0010517A (pt) * | 1999-03-26 | 2002-01-08 | Du Pont Pharm Co | Métodos de formação de imagem de um trombo, de um êmbolo pulmonar, de um trombo arterial e de um trombo coronariano |
| US6808698B1 (en) | 1999-03-26 | 2004-10-26 | Bristol-Myers Squibb Pharma Company | Method for localization of blood clots |
| US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| US20030220646A1 (en) * | 2002-05-23 | 2003-11-27 | Thelen Sarah L. | Method and apparatus for reducing femoral fractures |
| US6534038B2 (en) | 2000-04-07 | 2003-03-18 | Bristol-Myers Squibb Pharma Company | Ternary ligand complexes useful as radiopharmaceuticals |
| JP2004512382A (ja) | 2000-11-03 | 2004-04-22 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | 心臓灌流および心臓炎症の２核種同時イメージング |
| GB0031592D0 (en) * | 2000-12-28 | 2001-02-07 | Nycomed Amersham Plc | Stabilised radiopharmaceutical compositions |
| HUP0401904A3 (en) * | 2001-08-08 | 2009-01-28 | Bristol Myers Squibb Pharma Co | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
| US6838074B2 (en) | 2001-08-08 | 2005-01-04 | Bristol-Myers Squibb Company | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US7317104B2 (en) | 2003-06-13 | 2008-01-08 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
| US7319149B2 (en) * | 2003-06-13 | 2008-01-15 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
| BRPI0412824A (pt) * | 2003-07-24 | 2006-09-26 | Bracco Imaging Spa | composições radiofarmacêuticas estáveis e métodos para suas preparações |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| EP1896086A1 (en) * | 2005-06-30 | 2008-03-12 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
| EP1950205A4 (en) * | 2005-10-19 | 2010-07-07 | Dainippon Sumitomo Pharma Co | METHOD FOR STABILIZING AN ISOXAZOLE COMPOUND |
| US7465795B2 (en) * | 2005-12-20 | 2008-12-16 | Astrazeneca Ab | Compounds and uses thereof |
| RU2008122405A (ru) * | 2005-12-20 | 2010-01-27 | Астразенека Аб (Se) | Замещенные производные циннолина в качестве модуляторов гамма-рецепторов и способ их синтеза |
| US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| TW200911760A (en) * | 2007-06-19 | 2009-03-16 | Astrazeneca Ab | Compounds and uses thereof |
| CA2710039C (en) | 2007-12-26 | 2018-07-03 | Critical Outcome Technologies, Inc. | Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| ES2481042T3 (es) | 2008-12-29 | 2014-07-29 | Sanofi | Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y uso terapéutico como activadores de HIF |
| FR2949468B1 (fr) * | 2009-08-28 | 2011-09-30 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique |
| AU2009334570B2 (en) * | 2008-12-29 | 2016-06-09 | Sanofi | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof |
| FR2940652B1 (fr) * | 2008-12-29 | 2011-02-11 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique |
| CA2999435A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| FR2967671A1 (fr) * | 2010-11-24 | 2012-05-25 | Pf Medicament | Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses |
| CN110818624B (zh) * | 2019-11-22 | 2022-11-22 | 华东理工大学 | 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用 |
| CN112999369B (zh) * | 2021-03-03 | 2022-02-25 | 江苏元本生物科技有限公司 | 一种her2亲合体放射性核素标记物组合物及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427646A (en) | 1981-04-02 | 1984-01-24 | Research Corporation | Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo |
| US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
| US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
| CA1300608C (en) * | 1985-05-10 | 1992-05-12 | Edward A. Deutsch | 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo |
| GB8624272D0 (en) * | 1986-10-09 | 1986-11-12 | Amersham Int Plc | Cationic complexes of tc-99m |
| US5217705A (en) | 1987-09-25 | 1993-06-08 | Neorx Corporation | Method of diagnosing blood clots using fibrin-binding proteins |
| WO1989005150A1 (en) | 1987-12-10 | 1989-06-15 | La Jolla Cancer Research Foundation | Conformationally stabilized cell adhesion peptides |
| US5300278A (en) * | 1988-03-09 | 1994-04-05 | Cis Bio International | Process for the preparation of 99m Tc, 186 Re or 188 Re nitride complexes usable as radiopharmaceutical products |
| GB8808414D0 (en) * | 1988-04-11 | 1988-05-11 | Amersham Int Plc | Ligands & cationic complexes thereof with technetium-99m |
| EP0412115A4 (en) | 1988-04-29 | 1991-11-13 | New England Deaconess Hospital Corporation | Hybrid peptides and methods of their use |
| US5002754A (en) * | 1988-06-15 | 1991-03-26 | University Of Cincinnati | Technetium (III/II) imaging agents |
| HUT55799A (en) | 1988-09-29 | 1991-06-28 | Biogen Inc | Process for producing hirudine-like peptides |
| US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| US5270030A (en) | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| GB8902362D0 (en) * | 1989-02-03 | 1989-03-22 | Amersham Int Plc | Cationic complexes of technetium-99m |
| US5206370A (en) * | 1989-02-24 | 1993-04-27 | Johnson Matthey, Inc. | Certain pyridyl hydrazines and hydrazides useful for protein labeling |
| IL93432A (en) * | 1989-02-24 | 1994-02-27 | Johnson Mathey Inc | Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions |
| US4957728A (en) * | 1989-05-19 | 1990-09-18 | University Of Cincinnati | Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans |
| US4917879A (en) * | 1989-05-19 | 1990-04-17 | University Of Cincinnati | 99MTC(III) myocardial imaging agents that are effective in humans |
| GB8914020D0 (en) | 1989-06-19 | 1989-08-09 | Antisoma Ltd | Synthetic peptides for use in thrombus detection |
| EP0410537A1 (en) | 1989-07-28 | 1991-01-30 | Merck & Co. Inc. | Fibrinogen receptor antagonists |
| GB8919488D0 (en) * | 1989-08-29 | 1989-10-11 | Amersham Int Plc | New cores for technetium radiopharmaceuticals |
| ZA907743B (en) | 1989-10-03 | 1991-07-31 | Merrell Dow Pharma | Radiolabeled anticoagulant peptides |
| US5086069A (en) | 1990-02-05 | 1992-02-04 | Rorer Pharmaceutical Corporation | Anti-thrombotic peptide and pseudopeptide derivatives |
| US5137877B1 (en) * | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| FR2664166A1 (fr) * | 1990-07-04 | 1992-01-10 | Cis Bio Int | Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques. |
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| AU8730691A (en) * | 1990-09-28 | 1992-04-28 | Neorx Corporation | Polymeric carriers for release of covalently linked agents |
| US5112594A (en) * | 1991-04-04 | 1992-05-12 | Mallinckrodt Medical, Inc. | Kit for preparing a technetium-99m myocardial imaging agent |
| US5925331A (en) | 1992-05-21 | 1999-07-20 | Diatide, Inc. | Technetium-99m labeled peptides for thrombus imaging |
| CA2101942C (en) | 1991-02-08 | 2001-01-30 | Richard T. Dean | Technetium-99m labeled polypeptides for imaging |
| FR2679452B1 (fr) * | 1991-07-22 | 1993-11-12 | Cis Bio International | Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation. |
| US5362852A (en) * | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| GB2268494B (en) | 1992-07-08 | 1996-08-21 | Kenneth Francis Prendergast | Imaging compositions |
| FR2698272B1 (fr) * | 1992-11-20 | 1994-12-30 | Cis Bio Int | Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé. |
| US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
-
1995
- 1995-06-07 US US08/476,296 patent/US5750088A/en not_active Expired - Fee Related
-
1996
- 1996-05-30 IL IL11846896A patent/IL118468A0/xx unknown
- 1996-06-04 HR HR08/476,296A patent/HRP960250A2/hr not_active Application Discontinuation
- 1996-06-06 MY MYPI96002227A patent/MY133974A/en unknown
- 1996-06-07 WO PCT/US1996/009766 patent/WO1996040637A1/en not_active Ceased
- 1996-06-07 SI SI9620076A patent/SI9620076B/sl unknown
- 1996-06-07 CN CN96196141A patent/CN1192733A/zh active Pending
- 1996-06-07 MX MX9709126A patent/MX9709126A/es unknown
- 1996-06-07 JP JP9501990A patent/JPH11507364A/ja not_active Ceased
- 1996-06-07 AT AT96919289T patent/ATE233241T1/de not_active IP Right Cessation
- 1996-06-07 CA CA002222183A patent/CA2222183A1/en not_active Abandoned
- 1996-06-07 CZ CZ973801A patent/CZ380197A3/cs unknown
- 1996-06-07 EP EP96919289A patent/EP0832068B1/en not_active Expired - Lifetime
- 1996-06-07 KR KR1019970709054A patent/KR19990022573A/ko not_active Ceased
- 1996-06-07 ZA ZA9604854A patent/ZA964854B/xx unknown
- 1996-06-07 DE DE69626392T patent/DE69626392T2/de not_active Expired - Fee Related
- 1996-06-07 NZ NZ310799A patent/NZ310799A/xx unknown
- 1996-06-07 AR ARP960103028A patent/AR003959A1/es not_active Application Discontinuation
- 1996-06-07 BR BR9609003-0A patent/BR9609003A/pt not_active Application Discontinuation
- 1996-06-07 SK SK1634-97A patent/SK163497A3/sk unknown
- 1996-06-07 ES ES96919289T patent/ES2193245T3/es not_active Expired - Lifetime
- 1996-06-07 EA EA199800025A patent/EA000742B1/ru not_active IP Right Cessation
- 1996-06-07 EE EE9700313A patent/EE9700313A/xx unknown
- 1996-06-07 AU AU61661/96A patent/AU718683B2/en not_active Ceased
- 1996-06-07 PL PL96323995A patent/PL323995A1/xx unknown
- 1996-06-07 HU HU9901469A patent/HUP9901469A3/hu unknown
-
1997
- 1997-10-23 US US08/956,313 patent/US6015904A/en not_active Expired - Fee Related
- 1997-12-05 NO NO975678A patent/NO975678L/no not_active Application Discontinuation
- 1997-12-05 LT LT97-191A patent/LT4380B/lt not_active IP Right Cessation
-
1998
- 1998-01-28 LV LVP-97-247A patent/LV12044B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003959A1 (es) | Reactivo para preparar un grupo biologicamente activo conectado a un grupo hidrazona estable, conjunto de elementos para preparar un agente radio-farmaceutico y compuesto de hidrazona estable. | |
| ES2179196T3 (es) | Complejos radiofarmacos ternarios. | |
| CL2004001128A1 (es) | Compuestos derivados de halogenopirimidinas aril eter; composicion pesticida; procedimiento de preparacion; compuestos intermediarios; y uso del compuesto como agente pesticida. | |
| DK0630265T3 (da) | Technetium-99m mærkede peptider til afbildning af inflammation | |
| BR0210713A (pt) | Processo para a produção de um traçador 18f-rotulado, composto, kit radiofarmacêutico, cartucho para um kit radiofarmacêutico, e, método para obtenção de uma imagem de pet diagnóstica | |
| CY1106860T1 (el) | Δομες χρωστικων ευαισθητες σε οξεα και διασπωμενες ενζυμικα για τη διαγνωστικη με ακτινοβολια εγγυς υπερυθρου και για τη θεραπεια | |
| BR9607933A (pt) | Reagente para preparar um radiofarmacêutico agente de formação de imagem cintigráfica e radioterapêutico complexo composição kit para preparar uma preparação radiofarmacêutica processo para rotular um reagente para formar uma imagem de um sítio e para fazer um reagente composição de matéria e uso do reagente | |
| UA32577C2 (uk) | Радіомічена сполука для утворення зображення тромбів при радіонуклідній діагностиці, радіофармацевтичний препарат та радіофармацевтична композиція на їх основі та комплект для приготування радіофармацевтичних препаратів | |
| ES8404857A1 (es) | Un procedimiento para preparar un anticuerpo monoclonal para un antigeno asociado a un tumor. | |
| BRPI0519317A2 (pt) | mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer | |
| DE69912983D1 (de) | Wassermischbare pharmazeutische zusammensetzungen enthaltend paclitaxel | |
| Washburn et al. | DL-[Carboxyl-11C] tryptophan, a potential agent for pancreatic imaging; production and preclinical investigations | |
| BR9809785A (pt) | Composto de ligação de receptor de calcitonina, reagente, agente de formação de imagem cintigráfica, composição, agente radio-terapêutico, complexo, kit para preparar uma preparação radio-farmacêutica, processos para rotular o reagente, para fabricar o reagente, e, uso do reagente | |
| DE69841322D1 (de) | Hepatitis c rezeptorprotein cd81 | |
| CO2021017708A2 (es) | Ligandos de antígeno de membrana específico de próstata (psma) y sus usos | |
| BR0314716A (pt) | Anticorpos de subunidade alfa de lfa-1 e métodos de uso | |
| Pallares et al. | Development of an actinium-225 radioimmunoconjugate for targeted alpha therapy against SARS-CoV-2 | |
| ES2165971T3 (es) | Suspensiones de liposomas como agentes de contraste para la imagineria de la sangre. | |
| BR0108609A (pt) | Anticorpo com especificidade pelo câncer de cólon | |
| ES2032309T3 (es) | Compuestos de formazano complejo con cobre, procedimiento para su preparacion y su aplicacion como colorantes. | |
| Naqvi et al. | Radiosynthesis and preclinical studies of 177Lu-labeled sulfadiazine: a possible theranostic agent for deep-seated bacterial infection | |
| PL365279A1 (en) | Biotin-derivates and their conjugates with chelating agents | |
| ES2151572T3 (es) | Benzoilguanidinas sustituidas con trifluoropropilo y su empleo como medicamento o agente de diagnostico. | |
| BR9913627A (pt) | Uso de um derivado de antraciclina para o tratamento de um tumor no fìgado | |
| DE68914087D1 (de) | Spezifische Liganden für Östrogen- und Progestagen-Steroidhomonrezeptoren, deren Verwendung und Synthesezwischenprodukte. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |